Haisco Pharmaceutical (SHE:002653) obtained approval from China's drug regulator to conduct clinical trials for its HSK51155 tablets.
The oral drug candidate is being developed for the treatment of pain-related conditions, according to a filing with the Shenzhen bourse on Wednesday.
Shares of the company were down nearly 4% in recent trade.